Envoy Medical (COCH) Q3 2026 earnings review
Envoy Medical's implant trial advances, but its cash reserves shrink
Envoy Medical, a maker of fully implanted hearing devices, advanced its flagship ear implant trial while its cash reserve shrank. All 56 patients passed their six-month checkups, and the first 10 patients raised their average word recognition score to 53% at one year. However, chief executive Brent Lucas now expects to submit the final regulatory module a few months after early second-quarter 2027 visits, and by our math its $15 million cash balance covers less than three quarters of spending.
| Cash on hand | $14.6M down from $19.7M in Q2 |
|---|---|
| Q3 operating cash burn | $5.0M by our math, ~2.9 quarters of cash left |
| Stage 1 12-month word score | 53.2% +38 percentage points from baseline |
| Final FDA module timeline | Mid-2027 a few months after early Q2 2027 visits |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because steady clinical progress on the Acclaim implant is balanced by a tightening cash timeline. Passing the six-month trial mark and getting a Delaware lawsuit dismissed without payment reduced clinical and legal risk. The caution: accrued bills reached $12 million, and slipping the final regulatory filing to a few months after spring data collection puts the submission right at the edge of the company's current cash.
The question now is whether the company can fund its final regulatory submission without another dilutive stock sale. Either clinical progress triggers the exercise of up to $48 million in existing warrants from the February financing, or management must raise fresh capital before mid-2027. Cash balances and warrant exercises over the next two quarters will settle it.
🐂 Bull Case
All 56 Patients Reached Six-Month Trial Mark
Envoy Medical is developing the Acclaim cochlear implant, a hearing device placed entirely under the skin with no external microphone. After the third quarter ended, all 56 patients in its pivotal US trial passed their six-month checkups, and the company sent the second of four application parts to the Food and Drug Administration (FDA).
"We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027," chief executive Brent Lucas said. Because the agency evaluates effectiveness at 12 months, passing the halfway mark keeps the fourth and final regulatory filing on schedule for a few months after those spring 2027 visits.
What to watch: the third application module submission to the FDA and full 12-month patient retention early in the second quarter of 2027. Keeping all 56 patients through the one-year mark would let the hearing-implant maker submit its final clinical module on time.
First Ten Patients Improved Word Scores Further
The primary test for the Acclaim trial measures how well patients recognize single-syllable words at 12 months. In the first stage of the trial, the initial 10 participants scored an average of 53.2% on the Consonant-Nucleus-Consonant (CNC) word test at one year, up from 15.2% before surgery.
That 38.0 percentage point gain improved on the 24.0 percentage point increase those same patients recorded at six months. Because hearing performance strengthened between month six and month 12, the early group sets a favorable benchmark for the remaining 46 patients now moving through the second half of their follow-up window.
What to watch: pooled 12-month word recognition scores for the full 56-patient trial in the second quarter of 2027. A similar gain across the larger group would support the efficacy claim in the final FDA module.
Atlas Lawsuit Dismissed With Zero Payout
Envoy Medical faced a lawsuit in the Delaware Court of Chancery from Atlas Merchant Capital SPAC Fund I LP tied to its public listing. On October 6, 2026, the two sides signed a dismissal agreement that ended all claims with prejudice, meaning Atlas cannot refile them.
The case was "terminated without any payment by the Company or the other defendants," Envoy Medical said. General and administrative expenses still rose 6.3% from a year ago to $2.1 million in the third quarter on pay and professional fees, so ending the lawsuit removes a legal drain on cash.
What to watch: general and administrative spending in the fourth quarter of 2026. A drop below $2.0 million would show that ending the Delaware litigation lowered outside legal bills.
🐻 Bear Case
Cash Covers Under Three Quarters of Spending
"We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027," chief executive Brent Lucas said. However, the balance sheet shows that current cash barely reaches the middle of 2027.
- Cash on hand: $14.6 million on September 30, down from $19.7 million in June
- Third-quarter operating cash burn: $5.0 million by our math, after $5.5 million in the second quarter
- Nine-month operating cash burn: $16.5 million, up 32.2% from $12.5 million a year ago
By our math, $14.6 million covers 2.9 quarters at the third-quarter spending pace, taking the Minnesota company only to June 2027. Because management plans to submit the final FDA module a few months after early second-quarter data collection, cash runs out right around the filing date and well before commercial launch. In the second quarter, the company also closed its $15 million at-the-market share sale program.
What to watch: cash raised from milestone-linked warrants or new stock sales over the next two quarters. Without warrant exercises from its February 2026 financing, the device maker will need a new financing deal to fund FDA review.
Unpaid Bills Rose While Cash Dropped
Envoy Medical slowed its cash outflow in the first nine months of 2026 by letting short-term bills accumulate on its balance sheet. Accrued expenses climbed 51.9% from the end of 2025 to $11.6 million, up from $9.7 million at the end of March.
Total current liabilities reached $14.3 million, nearly matching the $14.6 million cash balance. In addition, the company recorded $1.3 million in unpaid Series A preferred stock dividends in the third quarter and $3.9 million over nine months. If vendors require cash payment on those accrued bills, the cash runway will shrink below three quarters.
What to watch: accrued expenses on the fourth-quarter balance sheet. A drop in accrued liabilities alongside a larger operating cash outflow would mean the company had to pay down those short-term obligations in cash.
Commercial Middle-Ear Implant Still Loses Money
Envoy Medical has sold its FDA-approved Esteem active middle ear implant since 2010, but the product brings in almost no money. Third-quarter revenue was $66 thousand, and nine-month sales fell 6.0% from a year ago to $156 thousand.
Cost of goods sold was $244 thousand in the quarter, so making and servicing the device cost nearly four times its sales. Sales and marketing spending fell 61.2% from a year ago to $157 thousand because of the "reallocation of field clinical specialists to research and development activities in support of the clinical trial," the company said, leaving the commercial product without sales support.
What to watch: quarterly revenue and cost of goods sold for the Esteem implant. Continued gross losses mean the approved device drains cash rather than helping pay for the Acclaim trial.
👓 Other Themes
Patent Portfolio Expanded to 97 Granted Patents
During the third quarter, regulators in Canada and Hong Kong granted Envoy Medical new patents covering implantable cochlear system design and middle-ear sensor signal processing. Those additions brought the global portfolio to 97 granted patents — 40 in the United States and 57 abroad — up from 47 reported in February 2026, with another 35 applications awaiting review.
💲 Other KPIs
Up nearly fivefold from 2.19 million a year ago. The jump stems from the February 2026 financing that raised $30.0 million in gross proceeds through common stock, pre-funded warrants and milestone warrants. That higher share count cut the third-quarter net loss per share to $0.50 from $3.55 a year earlier, even though operating losses grew.
Swung from a $0.75 million net expense a year ago to a $1.47 million non-cash gain this quarter across private, public and forward-purchase warrants. Warrant liabilities shrink when the underlying share value drops, creating an accounting gain. Excluding those non-cash warrant gains, the third-quarter net loss attributable to common stockholders was $6.71 million by our math.
Edged down 2.3% from $1.55 million at the end of 2025 and 4.4% from $1.58 million in June. Now that all 56 clinical trial patients have received their Acclaim implants, Envoy Medical is using fewer device units in research and development while commercial Esteem sales remain minimal.
🔮 Guidance
Unchanged. Envoy Medical still expects all 56 trial participants to finish their 12-month checkups early in the second quarter of 2027. That schedule matches the one-year anniversary of the final patient implant completed on March 11, 2026, and all 56 participants have already passed the six-month mark.
Pushed back slightly. Last quarter the company targeted the second quarter of 2027 for its fourth and final FDA application module, which holds the 12-month clinical trial results. Management now plans to submit that final module a few months after early second-quarter data collection ends, shifting the likely filing into the third quarter of 2027.
❓ Key Questions
What clinical milestones trigger the $48 million in warrants?
In the first quarter, management noted up to $48 million in potential gross proceeds from milestone-linked warrants. Investors need to know the exact clinical or regulatory triggers and exercise prices to judge whether warrant cash will arrive before mid-2027.
What makes up the $11.6 million in accrued expenses?
Accrued expenses rose by $4.0 million over the first nine months of 2026 and now equal 80% of the cash balance. Management has not disclosed how much of that figure is owed to clinical trial sites versus accrued preferred dividends.
What is the target score for the 12-month endpoint?
The first 10 patients improved their average word recognition score by 38 percentage points to 53.2% at 12 months. Management has not stated the minimum statistical threshold agreed with the FDA for the full 56-patient group to pass the trial.
When will the third FDA application module be submitted?
Envoy Medical submitted the first module in the second quarter and the second module after the third quarter ended. Knowing when the third module goes to the FDA will show if non-clinical review work is finished before final patient data arrives.